Martin H. Voss, MD, and Moshe Ornstein, MD, explore non-clear cell renal cell carcinoma and the potential impact of clinical trials on the evolution of treatment approaches.
August 5th 2024
Laurence Albiges, MD, PhD, presents a case study of a 56-year-old female patient experiencing left-sided flank pain and discusses the diagnostic approach and potential treatment options.
August 12th 2024
A key opinion leader explores the evolution of the treatment landscape for patients with advanced non-clear cell renal cell carcinoma (nccRCC), highlighting recent treatment options and sharing insights on factors influencing the selection of appropriate therapies.
August 19th 2024
Laurence Albiges, MD, PhD, analyzes the long-term follow-up data from the phase 2 KEYNOTE-B61 study, highlighting the observed overall survival (OS) rate associated with adjuvant pembrolizumab.
August 26th 2024
A key opinion leader discusses alternative therapies for the first-line treatment of advanced non-clear cell renal cell carcinoma (RCC), focusing on the PAPMET regimen and the results of a relevant Phase 2 clinical study.
September 3rd 2024
Dr. Laurence Albiges, MD, PhD, reviews the recent findings presented at the American Society of Clinical Oncology (ASCO) 2024 meeting, specifically focusing on the results of the phase 3 STELLAR trial.
September 9th 2024
In her concluding remarks, Laurence Albiges, MD, PhD, shares her final thoughts and expresses optimism for the future landscape of renal cell carcinoma treatments.